Molecular markers in myeloproliferative disorders: from classification to prognosis?
The recent description of molecular markers in patients with myeloproliferative disorders (MPDs) has raised several questions: does the presence of multiple markers coincide in individual patients or can a patient acquire some markers selectively? Do the markers distinguish molecular categories of MPDs? Do these categories coincide with the clinically defined subgroups of MPDs: PV, ET and IMF? If not, which system of categorization is more useful to the patient and his physician, the molecular one or the clinical one, and why? The present review will summarize the current knowledge of molecular markers in MPDs and discuss today's answers to the above questions. Since our knowledge of the molecular basis of MPDs is rapidly expanding, it is my hope that this review will soon be outdated.
Pahl
Heike L
HL
Division of Experimental Anaesthesiology, Center for Clinical Research University, Hospital Freiburg, Breisacher Street 66 79106, Freiburg, Germany. pahl@uni-freiburg.de
D000951:Antigens, Neoplasm / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis*; D002999:Clone Cells / Q000473:pathology; D006801:Humans; D009196:Myeloproliferative Disorders / Q000145:classification* / Q000175:diagnosis*; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000032:analysis
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D011956:Receptors, Cell Surface